Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Real-World Sacituzumab Govitecan Reinforces Benefit in mTNBC
Real-World Sacituzumab Govitecan Reinforces Benefit in mTNBC
On the Frontlines of Metastatic Breast Cancer
Real-World Sacituzumab Govitecan Reinforces Benefit in mTNBC
Ryan Quigley
- Ryan Quigley
CME/CE Virtual Event
Data Meets Decision: Expert Approaches to Perioperative Immunotherapy in LA HNSCC
Multiple dates available
0.75 credits
Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs
Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs
CME/CE
Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs
Sara A. Hurvitz, MD, FACP; Tiffany Traina, MD
0.50 credits
- Sara A. Hurvitz, MD, FACP
- Tiffany Traina, MD
0.50 credits
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
MinuteCE®
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
Ticiana Leal, MD
0.50 program credits
- Ticiana Leal, MD
0.50 program credits
MinuteCE®
Beyond Checkpoint Blockade in SCLC: Emerging Antigen Targets and Treatment Strategies Across Disease Stages
Neal Ready, MD, PhD; Ticiana Leal, MD
0.50 credits 4 episodes
- Neal Ready, MD, PhD
- Ticiana Leal, MD
0.50 credits 4 episodes
Clinical Evidence on Emerging Antigen-Directed Strategies in ES-SCLC
Clinical Evidence on Emerging Antigen-Directed Strategies in ES-SCLC
MinuteCE®
Clinical Evidence on Emerging Antigen-Directed Strategies in ES-SCLC
Ticiana Leal, MD
0.50 program credits
- Ticiana Leal, MD
0.50 program credits
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
MinuteCE®
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
Neal Ready, MD, PhD
0.50 program credits
- Neal Ready, MD, PhD
0.50 program credits
Exploring Treatment Strategies in epNEC: The Emerging Role of DLL3
Exploring Treatment Strategies in epNEC: The Emerging Role of DLL3
Project Oncology®
Exploring Treatment Strategies in epNEC: The Emerging Role of DLL3
Charles Turck, PharmD, BCPS, BCCCP; Jason Starr, DO
- Charles Turck, PharmD, BCPS, BCCCP
- Jason Starr, DO

Medical News

Medical News
36-Month Relapse Window May Define High-Risk Myeloma
07/30/2026
Read more
Medical News
Financial Toxicity Common in Insured Brazilian Cancer Patients
07/28/2026
Read more
Medical News
131I-LNTH-1095 Plus Enzalutamide in PSMA-Avid mCRPC
07/23/2026
Read more
Medical News
Perioperative Systemic Therapy vs Surgery Alone in Colorectal Peritoneal Metastases
07/21/2026
Read more

CME/CE

CME/CE In-Person & Virtual Event
The CELMoD Shift: Translating Protein Degradation Science Into Practice-Changing Myeloma Care
December 11, 2026
New Orleans, Louisiana
1.50 credits
The Survival Ceiling in ES-SCLC: Why Checkpoint Blockade Alone Is Not Enough
The Survival Ceiling in ES-SCLC: Why Checkpoint Blockade Alone Is Not Enough
MinuteCE®
The Survival Ceiling in ES-SCLC: Why Checkpoint Blockade Alone Is Not Enough
Neal Ready, MD, PhD
0.50 program credits
- Neal Ready, MD, PhD
0.50 program credits
CME/CE Virtual Event
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
Multiple dates available
1.00 credit
From Data to Decision: Patient Selection and Real-World Application
From Data to Decision: Patient Selection and Real-World Application
MinuteCE®
From Data to Decision: Patient Selection and Real-World Application
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 program credits
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 program credits

Clinical Practice

Urine RNA Panel Supports Less Invasive Bladder Cancer Surveillance
Urine RNA Panel Supports Less Invasive Bladder Cancer Surveillance
Project Oncology®
Urine RNA Panel Supports Less Invasive Bladder Cancer Surveillance
Can AI Imaging Improve Risk Stratification in Upper Tract Urothelial Carcinoma?
Can AI Imaging Improve Risk Stratification in Upper Tract Urothelial Carcinoma?
Project Oncology®
Can AI Imaging Improve Risk Stratification in Upper Tract Urothelial Carcinoma?
The Evidence Base: Key Trials and Emerging Data
The Evidence Base: Key Trials and Emerging Data
MinuteCE®
The Evidence Base: Key Trials and Emerging Data
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 program credits
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 program credits
MinuteCE®
Perioperative Immunotherapy in LA-HNSCC: From Evidence to Clinical Practice
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 credits 4 episodes
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 credits 4 episodes

Programs

NEW EPISODE
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
MinuteCE®
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
Aditya Bardia, MD, MPH, FASCO; Erica L. Mayer, MD, MPH
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
- Erica L. Mayer, MD, MPH
0.50 program credits
NEW EPISODE
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
MinuteCE®
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
NEW EPISODE
The Power of Timing: Therapies That Change Outcomes
The Power of Timing: Therapies That Change Outcomes
MinuteCE®
The Power of Timing: Therapies That Change Outcomes
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Project Oncology®
Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Alexandria May, PharmD, BCPS; Prithviraj Bose, MD
- Alexandria May, PharmD, BCPS
- Prithviraj Bose, MD